Topics
Diffuse midline glioma | Treatment | Clinical trials | CAR T-cell therapy
Home > Publications > Topics > Diffuse midline glioma > Treatment > Clinical trials > CAR T-cell therapy
*Monje
M, Mahdi J, Majzner R, Yeom K, Schultz LM, Richards RM, Barsan V,
Song KW, Kamens J, Baggott C, Kunicki M, Lim AS, Reschke A,
Mavroukakis S, Egeler E, Moon J, Patel S, Chinnasamy H, Erickson
C, Jacobs A, Duh AK, Rietberg SP, Tunuguntla R, Klysz DD, Fowler
C, Green S, Beebe B, Carr C, Fujimoto M, Brown AK, Petersen AG,
McIntyre C, Siddiqui A, Lepori-Bui N, Villar K, Pham K, Bove R,
Musa E, Reynolds W, Kuo A, Prabhu S, Rasmussen L, Cornell TT,
Partap S, Fisher PG, Campen CJ, Grant G, Prolo L, Ye X, Sahaf B,
Davis KL, Feldman SA, Ramakrishna S, Mackall C.
Sequential
intravenous and intracerebroventricular GD2-CAR T-cell therapy for
H3K27M-mutated diffuse midline gliomas.
medRxiv
[Preprint]. 2024 Jun 27:2024.06.25.24309146. doi:
10.1101/2024.06.25.24309146. PMID:
38978673. Interventional study.
ˍ